Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence

Swift elimination of undesirable cells is an important feature in tumour suppression and immunity. The tumour suppressor p53 and interferon-α and -β (IFN-α/β) are essential for the induction of apoptosis in cancerous cells and in antiviral immune responses, respectively, but little is known about their interrelationship. Here we show that transcription of the p53 gene is induced by IFN-α/β, accompanied by an increase in p53 protein level. IFN-α/β signalling itself does not activate p53; rather, it contributes to boosting p53 responses to stress signals. We show examples in which p53 gene induction by IFN-α/β contributes to tumour suppression. Furthermore, we show that p53 is activated in virally infected cells to evoke an apoptotic response and that p53 is critical for antiviral defence of the host. Our study reveals a hitherto unrecognized link between p53 and IFN-α/β in tumour suppression and antiviral immunity, which may have therapeutic implications.

[1]  K. Kinzler,et al.  Genetic determinants of p53-induced apoptosis and growth arrest. , 1996, Genes & development.

[2]  G. Matlashewski,et al.  Control of interferon signaling in human papillomavirus infection. , 2001, Cytokine & growth factor reviews.

[3]  C. Biron Interferons α and β as Immune Regulators—A New Look , 2001 .

[4]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[5]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[6]  H. Strander,et al.  Interferons and the tumor cell , 1996, Biotherapy.

[7]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[8]  H. Eguchi,et al.  Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of α‐interferon and oral tegafur/uracil , 2000, Journal of gastroenterology and hepatology.

[9]  T. Taniguchi,et al.  Essential and non‐redundant roles of p48 (ISGF3γ) and IRF‐1 in both type I and type II interferon responses, as revealed by gene targeting studies , 1996, Genes to cells : devoted to molecular & cellular mechanisms.

[10]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[11]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[12]  F. Belardelli,et al.  Endogenous type I interferons as a defense against tumors. , 2002, Cytokine & growth factor reviews.

[13]  T. Yagi,et al.  Enhanced proliferative potential in culture of cells from p53-deficient mice. , 1993, Oncogene.

[14]  D. Levy,et al.  ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. , 1996, Cytokine & growth factor reviews.

[15]  Michael G. Katze,et al.  Viruses and interferon: a fight for supremacy , 2002, Nature Reviews Immunology.

[16]  T. Taniguchi,et al.  Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 , 1994, Cell.

[17]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[18]  R. Metcalf,et al.  p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. , 1993, Carcinogenesis.

[19]  J. D. Weber,et al.  The ARF/p53 pathway. , 2000, Current opinion in genetics & development.

[20]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[21]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[22]  Y Taya,et al.  Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.

[23]  T. Taniguchi,et al.  Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. , 2000, Science.

[24]  D. Boothman,et al.  Delayed apoptotic responses associated with radiation-induced neoplastic transformation of human hybrid cells. , 1999, Cancer research.

[25]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[26]  P. Leder,et al.  Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. , 1997, Cancer research.

[27]  K C Zoon,et al.  Interferons and their actions. , 1987, Annual review of biochemistry.

[28]  R. Weinberg,et al.  Cell-cycle control and its watchman , 1996, Nature.

[29]  E. Baxter,et al.  p53 and tumour viruses: catching the guardian off-guard. , 1997, Trends in microbiology.

[30]  D. Levy,et al.  The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. , 2001, Cytokine & growth factor reviews.

[31]  J U Gutterman,et al.  Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[33]  S. Wadler,et al.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. , 1990, Cancer research.

[34]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[35]  B. Williams,et al.  Identification and characterization of an interferon (IFN)-stimulated response element-IFN-stimulated gene factor 3-independent signaling pathway for IFN-α , 1994 .

[36]  M. Oren Relationship of p53 to the control of apoptotic cell death. , 1994, Seminars in cancer biology.

[37]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[38]  E. Demaeyer,et al.  Interferons and other regulatory cytokines , 1988 .

[39]  Y Taya,et al.  Enhanced phosphorylation of p53 by ATM in response to DNA damage. , 1998, Science.

[40]  S Pestka,et al.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. , 1998, Cancer research.

[41]  S. Goodbourn,et al.  Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. , 2000, The Journal of general virology.

[42]  T. Taniguchi,et al.  Distinct and Essential Roles of Transcription Factors IRF-3 and IRF-7 in Response to Viruses for IFN-α/β Gene Induction , 2000 .

[43]  F. Hoppe-Seyler,et al.  Functional p53 protein in human papillomavirus-positive cancer cells. , 1995, Oncogene.

[44]  H. Hausen Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[45]  G. Evan,et al.  A matter of life and cell death. , 1998, Science.

[46]  J. Piette,et al.  Protein-binding elements in the promoter region of the mouse p53 gene. , 1990, Oncogene.

[47]  T. Veldman,et al.  Transcriptional Activation of the Telomerase hTERT Gene by Human Papillomavirus Type 16 E6 Oncoprotein , 2001, Journal of Virology.

[48]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[49]  T. Taniguchi,et al.  Delimitation and properties of DNA sequence: required for the regulated expression of human interferon-β gene , 1985, Cell.

[50]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.